MAVENIR
20.2.2024 08:01:34 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks, announces new developments on its OpenBeam™ massive MIMO (mMIMO) portfolio, powered by Qualcomm® QRU100 5G RAN platform, in continuation to previous years product launch update. Mavenir expands the OpenBeam™ portfolio by introducing the low-power next-generation 32TRX mMIMO variant along with a high-power 32TRX AAU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240219034877/en/
Mavenir OpenBeam massive MIMO 32TRX Active Antenna Unit. (Photo: Business Wire)
These next-generation mMIMO 32TRX Active Antenna Units (AAUs) introduce a new breed of open and interoperable radios that are green by design. OpenBeam™ mMIMO AAU delivers exceptional energy efficiency – resulting in one of the leanest mMIMO AAU footprints in the industry, offering substantial OpEx savings.
In addition to the current O-RAN 7.2b specification, the products are also engineered to support ULPI (Uplink Performance Improvement), allowing network operators to improve uplink performance of massive MIMO, minimize latency, and reduce fronthaul bandwidth, especially in urban settings where network capacity demand is high.
The portfolio consists of two discrete models that accelerate 5G mid-band rollouts:
- 32TRX AAU low power model: Offering one of the lowest footprints in the industry, the low power mMIMO AAU delivers 200W output power with 128 antenna elements at the lowest energy consumption. The solution is optimized for deployment in dense environments, driving faster installations and lower operational overheads.
- 32TRX AAU high power model: Mavenir’s high-performance mMIMO AAU capable of delivering 320W output power and offering 192 antenna elements. This platform supports larger instantaneous bandwidth, while the output power extends coverage, making it ideal for RAN sharing deployments.
The 32TRX AAU solutions deliver advanced energy-saving capabilities incorporating smart sleep-mode schemes that are activated during idle, low, and busy hour traffic. These automated capabilities can be further enhanced using AI/ML-based intelligence.
Paco Martin, Head of Open RAN at Vodafone Group: “We are pleased to see the broadening of Mavenir’s mMIMO portfolio with the addition of a low power, compact product fitting our single-operator and footprint-constrained sites, on top of the existing higher power leading solution. Further adoption of Qualcomm QRU100 5G RAN Platform keeps bringing high performance and power efficient Open RAN radios allowing us to deliver the best customer experience.”
BG Kumar, President, Access Networks, Platforms and MDE from Mavenir said: “With this continuing evolution and enhancement of our OpenBeam™ massive MIMO radio solutions, Mavenir is once again setting new standards in the industry for energy efficiency, sustainability and performance.”
“We are very pleased with this extension to Mavenir’s portfolio of high performing and power efficient Massive MIMO Radios, powered by Qualcomm QRU100 5G RAN Platform,” said Gerardo Giaretta, Vice President, Product Management, Qualcomm Technologies, Inc. “This is another great milestone in our ongoing collaboration with Mavenir, driving full-scale adoption of Open and Virtualized RAN.”
Mavenir’s OpenBeam™ full radio portfolio will be displayed at the upcoming Mobile World Congress in Barcelona, Feb 26-29, in Hall 2 Stand 2H60. For more on Mavenir’s presence at the show visit www.mavenir.com/mwc-2024
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 300+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.
For more information, please visit www.mavenir.com
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240219034877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom